Russian Journal of AllergyRussian Journal of AllergyРоссийский Аллергологический Журнал1810-88302686-682XPublishing House ABV Press54810.36691/RJA548ArticlesСтатьиResearch ArticleTOPICAL GLUCOCORTICOSTEROIDS IN ATOPIC DERMATITIS: FROM MECHANISMS TO CLINICAL PRACTICEТОПИЧЕСКИЕ ГЛЮКОКОРТИКОСТЕРОИДЫ ПРИ АТОПИЧЕСКОМ ДЕРМАТИТЕ: ОТ МЕХАНИЗМОВ К КЛИНИЧЕСКОЙ ПРАКТИКЕPampuraA NПампураАлександр Николаевичapampura@pedklin.ruResearch and Clinical Institute for Pediatrics at the Pirogov's Russian National Research Medical UniversityНИКИ педиатрии ГБОУ ВПО ГНИМУ им. Н.И. Пирогова15102014115NO5 (2014)№5 (2014)667110032020Copyright ©; 2014, Pharmarus Print MediaCopyright ©; 2014, Фармарус Принт Медиа2014Pharmarus Print MediaФармарус Принт Медиаhttps://rusalljournal.ru/raj/article/view/548

The article presents the current understanding of the genomic and nongenomic mechanisms of action of glucocorticoids, outlined data which cast doubt on the assertion of the positive role of nongenomic effects of this group of drugs for the treatment of patients suffering from atopic dermatitis, and the necessity of further experimental and clinical studies of corticosteroids with regard to the mechanisms of their action. Reasoned application of topical corticosteroids that have proven a high index of efficacy/safety with a wide range of dosage forms, which allows to optimize therapy for a particular patient.

Представлены современные сведения о геномных и внегеномных механизмах действия глюкокортикостероидов. Изложены данные, ставящие под сомнение утверждение о позитивной роли внегеномных эффектов данной группы препаратов для лечения больных, страдающих атопическим дерматитом (АтД), и обоснована необходимость дальнейших экспериментальных и клинических исследований применения глюкокортикостероидов с учетом механизмов их действия. Аргументировано применение топических глюкокортикостероидов, обладающих доказанным высоким индексом эффективности/безопасности, имеющих широкий выбор лекарственных форм, что позволяет максимально оптимизировать терапию у конкретного пациента.

topical glucocorticosteroidsmechanismgenomic effecttransrepressiontransactivationnongenomic effectatopic dermatitistherapyтопические глюкокортикостероидымеханизмгеномный эффекттрансрепрессиятрансактивациявнегеномный эффектатопический дерматиттерапияSulzberger M.B., Witten V.H. Effect oftopically applied compound F in selected dermatoses. J. Invest. Dermatol. 1952, v. 19, p.101-102.Fitzpatrick T.B., Griswold H.C., Hicks J.H. Sodium retention and edema from percutaneous absorption of fludrocortisone acetate. J. Am. Med. Assoc. 1955, v. 158, p. 1149-1152.Galon J., Franchimont D., Hiroi N. et al. Gene profiling reveals unknown enhancing and suppressive actions of glucocorticoids on immune cells. FASEB J. 2002, v. 16, p. 61-71.Kino T, De Martino M.U., Charmandari E. et al. Tissue glucocorticoid resistance/hypersensitivity syndromes. J. Steroid. Biochem. Mol. Biol. 2003, v. 85, p. 457-467.Strehl C., Buttgereit F. Unraveling the functions of the membrane-bound glucocorticoid receptors: first clues on origin and functional activity. Ann. N.Y Acad. Sci. 2014, v. 1318, p. 1-6.Pujols L., Mullol J., Perez M. et al. Expression of the human glucocorticoid receptor a and p isoforms in human respiratory epithelial cells and their regulation by dexamethasone. American Journal of Respiratory Cell and Molecular Biology. 2001, v. 24, p. 49-57.Almawi W.Y, Melemedjian O.K. Molecular mechanisms of glucocorticoid anti-proliferative effects: antagonism of transcription factor activity by glucocorticoid receptor. J. Leukoc. Biol. 2002, v. 71, p. 9-15.Grad I., Picard D. The glucocorticoid responses are shaped by molecular chaperones. Mol. Cell Endocrinol. 2007, v. 275, p. 2-12.Sakai D.D. et al. Hormone-mediated repression: a negative glucocorticoid response element from the bovine prolactin gene. Genes Dev. 1988, v. 2, p. 1144-1154.Nan Yang. Mechanisms of Altered Glucocorticoid Sensitivity. The University of Manchester. 2013, p. 221Beato M. Gene regulation by steroid hormones. Cell. 1989, v. 56, p. 335-344.Uva L., Miguel D., Pinheiro C. et al. Mechanisms of action oftopical corticosteroids in psoriasis. Int. J. Endocrinol. 2012, v. 2, ID 561018.Beck I.M., Berghe W.V., Vermeulen L. et al. Crosstalk in Inflammation: The Interplay of Glucorticoid Receptor-Based Mechanisms and Kinases and Phosphatases. Endocr. Rev. 2009, v. 30, p. 830-882.Schracke H., Rehwinkel H., Asadullah K. Dissociated glucocorticoid receptor ligands: compounds with an improved therapeutic index. Curr. Opin. Investig. Drugs. 2005, v. 6, p. 503-507.Barnes P.J. Anti-inflammatory actions of glucocorticoids: molecular mechanisms, Clin. Sci. (Lond). 1998, v. 94, p. 557-572.Buttgereit F., Wehling M., Burmester M. A new hypothesis of modular glucocorticoid actions. Arthritis Rheum. 1998, v. 41, p. 761-767.Adcock I.M., Nasuhara Y., Stevens D.A., Barnes PJ. Ligand-induced differentiation of glucocorticoid receptor (GR) trans-repression and transactivation: preferential targetting of NFkappaB and lack of I-kappaB involvement. Br. J. Pharmacol. 1999, v. 127, p. 1003-1011.Reddy T.E., Gertz J., Crawford G.E. et al. The hypersensitive glucocorticoid response specifically regulates period 1 and expression of circadian genes. Mol. Cell Biol. 2012, v. 32, p. 3756-3767.Duma D., Collins J.B., Chou J.W, Cidlowski J.A. Sexually dimorphic actions of glucocorticoids provide a link to inflammatory diseases with gender differences in prevalence. Sci. Signal. 2010, v. 3, p. 74.Haller J., Mikics E. The effects of non-genomic glucocorticoid mechanisms on bodily functions and the central neural system. A critical evaluation of findings. Front Neuroendocrinol. 2008, v. 29, p. 273-291.Solito E., Mulla A., Morris J.F. et al. Dexamethasone induces rapid serine-phosphorylation and membrane translocation of annexin 1 in a human folliculostellate cell line via a novel nongenomic mechanism involving the glucocorticoid receptor, protein kinase C, phosphatidylinositol 3-kinase, and mitogen-activated protein kinase. Endocrinology. 2003, v. 144, p.1164-1174.Croxtall J.D., van Hal P.T, Choudhury Q. et al. Different glucocorticoids vary in their genomic and non-genomic mechanism of action in A549 cells. Br. J. Pharmacol. 2002, v. 135, p. 511-519.Sun H.W., Miao C.Y., Liu L. et al. Rapid inhibitory effect of glucocorticoids on airway smooth muscle contractions in guinea pigs. Steroids. 2006, v. 71 p. 154-159.Greaves M.W., Gatti S. The use of glucocorticosteroids in dermatology. J. Dermatol. Treat. 1999, v. 10, p. 83-91.Yohn J.J., Weston W.L. Topical glucocorticosteroids. Curr. Probl. Dermatol. 1990, v. 2, p. 31-63.Gross K.L., Lu N.Z., Cidlowski J.A. Molecular mechanisms regulating glucocorticoid sensitivity and resistance. Mol. Cell Endocrinol. 2009, v. 300, p. 7-16.McKenzie A.W. Comparison of steroids by vasoconstriction. Br. J. Dermatol. 1966, v. 78, p. 182-183.Morley K.W., Dinulos J.G. Update on topical glucocorticoid use in children. Curr. Opin. Peadiatr. 2012, v. 24, p. 121-128.Кочергин Н.Г, Петрунин Д.Д. Современный взгляд на проблему выбора лекарственной формы средств наружной терапии. Клиническая дерматология и венерология. 2011, № 6, с. 84-92.